Salt Lake City, UTNCT07044635Now EnrollingIRB Ready

Oropharyngeal Squamous Cell Carcinoma Clinical Trial in Salt Lake City, UT

Access cutting-edge oropharyngeal squamous cell carcinoma treatment through this clinical trial at a research site in Salt Lake City. Study-provided care at no cost to qualified participants.

Sponsored by University of Utah

Quick Self-Assessment

See if you qualify for this Salt Lake City location

Preparing your pre-screening questions…

Expert Care in Salt Lake City

Access oropharyngeal squamous cell carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related oropharyngeal squamous cell carcinoma treatment provided free

Apply for This Salt Lake City Location

Check if you qualify for this oropharyngeal squamous cell carcinoma clinical trial in Salt Lake City, UT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Salt Lake City

    Convenient for UT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Salt Lake City site if eligible
  4. 4Begin participation

About This Oropharyngeal Squamous Cell Carcinoma Study in Salt Lake City

The goal of this study is to evaluate if a shorter course of therapy can improve the quality of life in patients receiving radiation therapy after trans-oral robotic surgery.

Sponsor: University of Utah

Who Can Participate

Inclusion Criteria

Participant aged ≥ 18 years.
Diagnosis of oropharyngeal squamous cell carcinoma.
Eligible to receive transoral robotic surgery.
If status is known, p16 positivity or HPV positivity by in situ hybridization on pathological sampling of lymph node or primary oropharyngeal tumor. If status not known at the time of step-1 registration, otherwise eligible participants may be enrolled and HPV/p16 status must be determined prior to step-2 registration.
Pre-operative TTMV-HPV DNA test collected or is planned to be collected. Pre-operative TTMV-HPV DNA may be collected anytime up until the day of surgery as long as it is prior to surgery.
Standard of care tests completed within 60 days of registration may be used for screening.
Tests results are not required to confirm eligibility for step 1 registration.
ECOG Performance Status ≤ 2
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria

History of prior mucosal head and neck cancer treated with radiation therapy
Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this study
Participant has smoked cigarettes within 1 month of registration
Prior systemic anti-cancer therapy or any investigational therapy ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter.
Known distant metastatic disease.
Current evidence of any condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, \[participants may not receive the drug through a feeding tube\], social/ psychological issues, etc.)
Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study. Step 2 Registration - Experimental Arm Inclusion Criteria:
Completion of trans-oral robotic surgery.
Pre- and post-operative TTMV-HPV DNA test results obtained.
P16 positivity or HPV positivity by in situ hybridization on pathological sampling of lymph node or primary oropharyngeal tumor
For participants of childbearing potential: Negative pregnancy test or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
\< 50 years of age:
Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and
Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
≥ 50 years of age:
Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or
Had radiation-induced menopause with last menses \>1 year ago; or
Had chemotherapy-induced menopause with last menses \>1 year
Participants of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.5.2. Exclusion Criteria:
Meets ALL of the following criteria for low-risk disease (Note: participants may meet some without being excluded):
Pre-operative TTMV-HPV DNA positive
Post-operative TTMV-HPV DNA negative
Disease: pT1 with ≤ 1 lymph nodes OR pT2N0
\<10 pack year smoking
No extranodal extension
Negative surgical margins
No perineural invasion
No lymphovascular invasion
Meets ANY of the following criteria for high-risk:
Post-operative TTMV-HPV DNA positive
Surgical margin positive --\>1 mm extranodal extension --≥ 5 lymph nodes
Current evidence of any condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, \[participants may not receive the drug through a feeding tube\], social/ psychological issues, etc.) Step 2 Registration - Exploratory Arm Inclusion Criteria
Completion of trans-oral robotic surgery.
Pre- and post-operative TTMV-HPV DNA test results obtained.
Meets ANY of the following criteria:
Post-operative TTMV-HPV DNA positive or indeterminate
Surgical margin positive
\>1 mm extranodal extension
≥5 lymph nodes
Pre-operative TTMV-HPV DNA score of ≤ 50
For participants of child bearing potential: Negative pregnancy test or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
\< 50 years of age:
Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and
Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
≥ 50 years of age:
Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or
Had radiation-induced menopause with last menses \>1 year ago; or
Had chemotherapy-induced menopause with last menses \>1 year
Participants of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.5.2. Exclusion Criteria
Pre-operative TTMV-HPV DNA score of \> 50.
Current evidence of any condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, \[participants may not receive the drug through a feeding tube\], social/ psychological issues, etc.).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Salt Lake City?

Yes, this clinical trial (NCT07044635) has an active research site in Salt Lake City, UT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Oropharyngeal Squamous Cell Carcinoma Treatment Options in Salt Lake City, UT

If you're searching for oropharyngeal squamous cell carcinoma treatment options in Salt Lake City, UT, this clinical trial (NCT07044635) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Salt Lake City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced oropharyngeal squamous cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all oropharyngeal squamous cell carcinoma clinical trials near you to find additional studies recruiting in your area.

More Head and Neck Cancer Trials in Salt Lake City, UT

See all head and neck cancer clinical trials recruiting in Salt Lake City — not just this study.

Browse Head and Neck Cancer Trials in Salt Lake City →

Browse More Trials by Condition

Head and Neck Cancer TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Salt Lake City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Salt Lake City, UT